Summary: Researchers report a promising approach to restore muscle function in an aggressive mouse model of amyotrophic lateral sclerosis (ALS) by combining grafted motor neurons with optical nerve stimulation. The method demonstrates that even muscles severely affected by ALS can be reinnervated and regain contractile strength when replacement motor neurons are guided and repeatedly stimulated.
This study presents compelling preclinical evidence for a potential assistive therapy that could be broadly applicable across ALS patients. Current treatments do not stop symptom progression because ALS involves complex, variable changes that cause motor neuron degeneration. The new approach bypasses those underlying molecular differences by replacing lost motor neurons and driving neuromuscular reconnection with light-based stimulation.
Key facts:
- Researchers grafted light-sensitive replacement motor neurons into a severe ALS mouse model and used optical nerve stimulation (ONS) to activate those neurons, enabling restored muscle control.
- To promote formation of mature neuromuscular junctions, the team applied a daily wireless optical stimulation regimen, producing a more-than tenfold improvement in muscle contraction force (reported improvements reached up to 13-fold after 21 days).
- Challenges remain before clinical use, including confirming the method with human motor neurons, ensuring long-term durability, and demonstrating broader safety and efficacy in diverse forms of motor neuron disease.
Source: Life
Overview: Scientists describe how grafted replacement motor neurons, engineered to respond to light, combined with optical nerve stimulation can restore innervation and improve muscle contractions in a highly aggressive mouse model of ALS. Published as an eLife Reviewed Preprint, the study is framed as a fundamental step demonstrating that targeted, optogenetic cell therapy can rewire neuromuscular connections even at advanced disease stages.
The findings raise the possibility of developing an assistive therapy that does not depend on correcting each patient’s distinct molecular pathology. Instead, by supplying healthy motor neurons and maintaining activity at the neuromuscular junction, the strategy aims to restore function across a range of ALS cases.
ALS, the most common adult motor neuron disease, typically begins with disruption of neuromuscular junctions—the specialized synapses linking motor nerve endings to muscle fibers. When these junctions break down, muscles lose innervation, leading to progressive weakness, paralysis and reduced life expectancy. Median survival after symptom onset is commonly cited in the range of 20–48 months.
Lead author Dr. Barney Bryson (MND Association Senior Non-Clinical Research Fellow and NIHR BRC UCL Excellence Fellow, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology) highlights the clinical challenge: the cellular and molecular drivers of motor neuron loss vary widely among patients, and there are currently no therapies that halt symptom progression.
Building on earlier proof-of-concept work in nerve injury models, Bryson and colleagues tested whether an optogenetic neural replacement strategy could reliably reinnervate muscles in the aggressive SOD1G93A mouse model of ALS. In their approach, donor motor neurons are genetically modified to be light-sensitive and implanted near target muscles. Optical nerve stimulation (ONS) using a small light source then activates those grafted neurons to drive muscle contractions.
A key early hurdle was preventing immune rejection of the grafted cells. The group evaluated tacrolimus, a common immunosuppressive used in organ transplantation, and found it unsafe in this ALS model. They instead used a targeted antibody, H57-597, which reduced rejection and allowed allogeneic motor neurons to survive and establish partial connections with host muscles. However, initial contractile forces remained weak, suggesting incomplete maturation of neuromuscular junctions.
Because neuromuscular junction formation and maintenance depend on activity, the team implemented a daily wireless optical stimulation regimen to drive regular contractions for one hour per day. After 21 days of this stimulation training, reinnervated muscles displayed a more-than tenfold increase in contraction force, with some measures reporting up to a 13-fold improvement. The stimulation paradigm also helped prevent atrophy of reinnervated muscle fibers.
These results indicate that muscles in a late-stage ALS model remain capable of accepting new motor inputs and regaining function when replacement neurons survive and are appropriately activated. The approach therefore provides a practical interface—an optogenetic cell therapy—that can selectively control targeted muscles via light.
The authors emphasize that important questions remain. It is necessary to validate the grafting technique with human motor neurons, to assess long-term stability and safety, and to test the approach in other motor neuron disease subtypes with longer disease courses. Clinical translation will require careful investigation of immunosuppressive strategies, scalable production of appropriate motor neuron types, and approaches to deliver and maintain safe optical stimulation in patients.
“Our study shows replacement motor neurons can reliably reinnervate target muscles in an advanced ALS model,” says senior author Professor Linda Greensmith (Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology). She notes that if translated to patients, using a broadly compatible motor neuron subtype could enable a single manufactured cell product to serve many muscles, offering a more efficient route to wide-scale treatment.
About this ALS research news
Author: Linda Greensmith
Source: eLife
Contact: Linda Greensmith – eLife
Image: The image is credited to Neuroscience News
Original research (open access): “An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of Amyotrophic Lateral Sclerosis” by Linda Greensmith et al., eLife (Reviewed Preprint).
Abstract
An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of Amyotrophic Lateral Sclerosis
ALS causes progressive motor neuron loss and neuromuscular transmission failure, resulting in muscle weakness, paralysis and premature death. No current treatments prevent motor neuron degeneration, denervation or paralysis. This study reports advances in an optogenetic neural replacement strategy that restores innervation of severely affected skeletal muscles in the SOD1G93A mouse model, providing a means to selectively control targeted muscles with optical stimulation. The work identifies an approach to ensure survival of allogeneic replacement motor neurons and shows that an optical stimulation training paradigm prevents atrophy of reinnervated fibers and produces a more-than tenfold increase in optically evoked contractile force. Together, these findings support further development of an assistive therapy that could benefit people with ALS.